[HTML][HTML] Axl as a mediator of cellular growth and survival

H Axelrod, KJ Pienta - Oncotarget, 2014 - ncbi.nlm.nih.gov
The control of cellular growth and proliferation is key to the maintenance of homeostasis.
Survival, proliferation, and arrest are regulated, in part, by Growth Arrest Specific 6 (Gas6) …

Therapeutic targeting of the Gas6/Axl signaling pathway in cancer

M Tanaka, DW Siemann - International journal of molecular sciences, 2021 - mdpi.com
Many signaling pathways are dysregulated in cancer cells and the host tumor
microenvironment. Aberrant receptor tyrosine kinase (RTK) pathways promote cancer …

Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs

X Lu, L Xiao, L Wang, DM Ruden - Biochemical pharmacology, 2012 - Elsevier
Hsp90 is a chaperone protein that interacts with client proteins that are known to be in the
cell cycle, signaling and chromatin-remodeling pathways. Hsp90 inhibitors act additively or …

[HTML][HTML] New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas

BT Mossman, A Shukla, NH Heintz… - The American journal of …, 2013 - Elsevier
Malignant mesothelioma (MM) is a relatively rare but devastating tumor that is increasing
worldwide. Yet, because of difficulties in early diagnosis and resistance to conventional …

Molecular changes in mesothelioma with an impact on prognosis and treatment

D Jean, J Daubriac… - … of pathology & …, 2012 - meridian.allenpress.com
Context.—In recent decades, research on malignant pleural mesothelioma (MPM) has been
developed to improve patients' outcomes by increasing the level of confidence in MPM …

SETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53

M Xu, Y Tu, W Bi, MZ Lundberg, I Klooster… - British Journal of …, 2023 - nature.com
Background Mutational inactivation of the SETDB1 histone methyltransferase is found in a
subset of mesothelioma, particularly in cases with near-haploidy and TP53 mutations …

Axl inhibitors as novel cancer therapeutic agents

Y Shen, X Chen, J He, D Liao, X Zu - Life sciences, 2018 - Elsevier
Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to
promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several …

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma

S Zhou, L Liu, H Li, G Eilers, Y Kuang, S Shi… - British journal of …, 2014 - nature.com
Background: Mesothelioma is a notoriously chemotherapy-resistant neoplasm, as is evident
in the dismal overall survival for patients with those of asbestos-associated disease. We …

S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab

MF Burbridge, CJ Bossard, C Saunier, I Fejes… - Molecular cancer …, 2013 - AACR
Aberrant activity of the receptor tyrosine kinases MET, AXL, and FGFR1/2/3 has been
associated with tumor progression in a wide variety of human malignancies, notably in …

Regulatory role of the 90-kDa-heat-shock protein (Hsp90) and associated factors on gene expression

AG Erlejman, M Lagadari, J Toneatto… - … et Biophysica Acta (BBA …, 2014 - Elsevier
The term molecular chaperone was first used to describe the ability of nucleoplasmin to
prevent the aggregation of histones with DNA during the assembly of nucleosomes …